Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
ODTX · Why this verdict
Why Odyssey Therapeutics (ODTX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.3/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Odyssey sits below the engine's quality floor at 3.0/10, with the engine also flagging operating margin compression to -6.8% and material insider selling among 2 of 5 value-trap signals. Bear case | Quality score should rise above 4.0 within 12 months if margin trends stabilize. | →Stable |
| CounterClinical-stage biotechs pre-commercialization structurally score poorly on margin-based quality metrics, which may not be diagnostic of the company's actual pipeline value. | ||
Odyssey Therapeutics shows a favorable asymmetry ratio of 4.13, driven by 61.9% modeled upside against a 15% downside case, clearing the engine's minimum threshold well above the 1.5 bar. Reward-to-risk math | The asymmetry ratio should stay above 3.0 for the favorable risk/reward setup to persist over the next 12 months. | →Stable |
| CounterAs a binary clinical-stage biotech below institutional reach, the modeled upside can evaporate instantly on a single negative trial readout, making the favorable asymmetry ratio fragile. | ||
The stock failed the engine's momentum gate at 2.2 versus a 4.5 threshold, with falling on-balance volume signaling distribution, or net selling pressure. Engine gate (failed) | Momentum score should recover above 4.5 within 2 quarters for the gate to clear. | →Stable |
| CounterMomentum readings this weak in a small-cap, thinly-traded biotech can be driven by a handful of large trades rather than a genuine broad-based negative trend. | ||
The company's most recent reported quarter missed estimates by -427.0%, and the next earnings report on 2026-08-07 represents a high-risk catalyst given the magnitude of the prior surprise. Earnings | The surprise magnitude should narrow substantially at the 2026-08-07 report for estimate reliability to improve. | →Stable |
| CounterA single data point of earnings history for a clinical-stage biotech is not statistically meaningful, and losses of this scale are typical and expected pre-revenue. | ||
Analysts see 90% upside to their price target, though the engine notes this signal is dampened by light analyst coverage. Sentiment breakdown | Analyst upside should narrow toward 40-50% as the stock price converges toward the target or as additional analyst coverage confirms the target over the next 12 months. | →Stable |
| CounterA 90% upside gap on light coverage can reflect a single analyst's stale or overly optimistic model rather than broad institutional conviction. | ||
Odyssey sits below the engine's quality floor at 3.0/10, with the engine also flagging operating margin compression to -6.8% and material insider selling among 2 of 5 value-trap signals.
→StableBear case
- Expectation
- Quality score should rise above 4.0 within 12 months if margin trends stabilize.
CounterClinical-stage biotechs pre-commercialization structurally score poorly on margin-based quality metrics, which may not be diagnostic of the company's actual pipeline value.
Odyssey Therapeutics shows a favorable asymmetry ratio of 4.13, driven by 61.9% modeled upside against a 15% downside case, clearing the engine's minimum threshold well above the 1.5 bar.
→StableReward-to-risk math
- Expectation
- The asymmetry ratio should stay above 3.0 for the favorable risk/reward setup to persist over the next 12 months.
CounterAs a binary clinical-stage biotech below institutional reach, the modeled upside can evaporate instantly on a single negative trial readout, making the favorable asymmetry ratio fragile.
The stock failed the engine's momentum gate at 2.2 versus a 4.5 threshold, with falling on-balance volume signaling distribution, or net selling pressure.
→StableEngine gate (failed)
- Expectation
- Momentum score should recover above 4.5 within 2 quarters for the gate to clear.
CounterMomentum readings this weak in a small-cap, thinly-traded biotech can be driven by a handful of large trades rather than a genuine broad-based negative trend.
The company's most recent reported quarter missed estimates by -427.0%, and the next earnings report on 2026-08-07 represents a high-risk catalyst given the magnitude of the prior surprise.
→StableEarnings
- Expectation
- The surprise magnitude should narrow substantially at the 2026-08-07 report for estimate reliability to improve.
CounterA single data point of earnings history for a clinical-stage biotech is not statistically meaningful, and losses of this scale are typical and expected pre-revenue.
Analysts see 90% upside to their price target, though the engine notes this signal is dampened by light analyst coverage.
→StableSentiment breakdown
- Expectation
- Analyst upside should narrow toward 40-50% as the stock price converges toward the target or as additional analyst coverage confirms the target over the next 12 months.
CounterA 90% upside gap on light coverage can reflect a single analyst's stale or overly optimistic model rather than broad institutional conviction.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Odyssey Therapeutics offers a favorable modeled risk/reward for a speculative clinical-stage biotech, but a momentum gate failure, below-floor quality, and a large recent earnings miss keep the setup firmly speculative.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.0/10data confidence 71%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| Moat | 5.5 |
| Piotroski F | 4.4 |
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.5 |
| MACD | 0.0 |
| OBV | 1.0 |
| MA position | 3.5 |
| Volume | 0.0 |
- ▸Volume distribution (falling OBV)
Sentiment
8.2/10data confidence 67%| Component | Sub-score |
|---|---|
| Analyst rating | 6.8 |
| Price target | 10.0 |
- ▸Light analyst coverage (3.0) — signal dampened
- ▸Analyst upside: 103%
Insider
5.0/10data confidence 50%Peer rank
4.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 5.0 |
Technical
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 9.2 |
| support resistance | 8.6 |
| 52w position | 5.5 |
| gap | 6.0 |
Risk (lower is worse)
6.1/10data confidence 80%| Component | Sub-score |
|---|---|
| short interest | 8.4 |
| days to cover | 6.4 |
| volatility | 0.0 |
| debt equity | 9.4 |
Catalyst
1.7/10data confidence 75%| Component | Sub-score |
|---|---|
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- ASYMMETRY:4.8>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:31d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:1.6<4.5
Warning (0)
none
Reward-to-Risk
4.82
Upside
+72.4%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.8B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 9.0 could not lift the engine output above the verdict floor. Failed gate signal: MOMENTUM:1.6<4.5.
The strongest dimensions are Value at 9.0, Sentiment at 8.2, and Technical at 7.3; the weakest are Momentum at 1.6, Catalyst at 1.7, and Quality at 3.0. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 4.82 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1High Asymmetry Speculative Upside
Trip ifAsymmetry ratio compresses below 2.0 within 2 quarters as downside risk materializes.
- P2Momentum Gate Failure Distribution
Trip ifMomentum score stays below 3.0 for 2 consecutive quarters.
- P3Quality Floor Value Trap Signals
Trip ifValue-trap signal count rises to 3 or more of 5, or quality score stays below 2.5 for 4 consecutive quarters.
- P4Large Earnings Miss Catalyst Risk
Trip ifEPS surprise stays below -100% at the 2026-08-07 report, repeating the magnitude of the prior miss.
- P5Strong Analyst Upside Light Coverage
Trip ifAnalyst upside stays above 80% for 2 consecutive quarters without the price moving toward the target, suggesting the target itself is unreliable.